MAPK3 and Parkinson disease: Using a 6-OHDA model of Parkinson’s disease, we show that D1R-mediated activation of PKA and ERK1/2 is at first enhanced by dopamine depletion, and partially attenuated by prolonged l-DOPA treatment.